Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits phosphatidylinositol-3-kinase with predominant activity against the alpha isoform (PI3Kα), including mutant p110α encoded by PIK3CA, reducing downstream AKT signalling and tumour-cell growth.
Indications / reported uses
In combination with fulvestrant for adults with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on or after an endocrine-based regimen
Treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) requiring systemic therapy in adults and paediatric patients aged 2 years and older under the US FDA Vijoice indication; the oncology and PROS formulations/labels are distinct
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Alpelisib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Alpelisib Permitted Daily Exposure (PDE) report (the Alpelisib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Alpelisib Occupational Exposure Limit (OEL) report (the Alpelisib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.